Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumor patients in China further provided prospects for precise and individualized targeted treatment. An ongoing phase II clinical trial, the PLATFORM study, is the first trial tailored for rare solid tumors in China, featured by molecule-guided therapeutics. With the promulgation of supportive policies to encourage the development of innovative drugs for rare tumors in China, opportunities will be provided for these patients and the gap will be filled in the treatment of rare tumors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832829 | PMC |
http://dx.doi.org/10.15252/emmm.202216415 | DOI Listing |
Front Oncol
January 2025
Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Chondrosarcoma-like malignant giant cell tumor (GCT) of the rib is an extremely rare and aggressive tumor, particularly in adolescents. This case report describes a 19-year-old female presenting with a GCT of the rib with chondrosarcomatous differentiation, highlighting the challenges posed by its unusual location and pathological complexity. Multidisciplinary diagnostic approaches, including advanced imaging, immunohistochemistry (IHC), and pathology, were essential for confirming the diagnosis.
View Article and Find Full Text PDFJ Anus Rectum Colon
January 2025
Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.
Colorectal cancer with gut-associated lymphoid tissue (GALT) carcinoma histopathology is particularly rare in very elderly patients. GALT is characterized by submucosal localization and prominent lymphoid infiltration with germinal center formation within tumor-infiltrating lymphocytes. This study aims to report a case of colorectal cancer with GALT carcinoma histopathology in a very elderly patient and to provide a comprehensive literature review.
View Article and Find Full Text PDFCureus
December 2024
Saudi Internal Medicine Residency Training Program, Ministry of Health, Jeddah, SAU.
Eccrine acrospiromas, also known as hidradenomas, are rare benign tumors that develop from the eccrine sweat glands. Hidradenoma is a multilobular, nonencapsulated, well-circumscribed dermal nodule that may involve the epidermis and extend into the subcutaneous fat. The etiology and prevalence of nodular hidradenoma are not well defined, but it is noted that it can occur spontaneously or traumatically.
View Article and Find Full Text PDFCureus
December 2024
Internal Medicine/Pulmonary Critical Care, BronxCare Health System/Icahn School of Medicine at Mount Sinai, New York City, USA.
Ovarian sex cord-stromal tumors (SCST) are a rare subset of ovarian neoplasms originating from supportive tissues surrounding oocytes. Despite their rarity, prompt diagnosis and management are crucial due to their potential for diverse clinical presentations and the need to optimize patient outcomes. A 25-year-old female patient was initially diagnosed with pyelonephritis but later discovered to have a large right adnexal mass suspected to be a tubo-ovarian abscess.
View Article and Find Full Text PDFJ Neurol Surg B Skull Base
February 2025
Department of Otorhinolaryngology, Tan Tock Seng Hospital, Singapore.
Primary extracranial meningiomas (PEMs) of the sinonasal tract with no intracranial extension are rare. Our study presents the largest systematic review to date, providing a comprehensive overview and comparison of the characteristics, treatment, and prognosis of PEMs, with comparison to primary intracranial meningiomas (PIMs). A systematic review was conducted according to the PRISMA guidelines on PubMed, Embase, and Google Scholar up to November 1, 2022.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!